58th ASH Annual Meeting to Celebrate Major Advances in Hematology Research

(WASHINGTON, November 30, 2016) – The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, will host more than 27,000 attendees from around the world to highlight groundbreaking scientific research and the latest advances in patient care at its 58th annual meeting, December 3-6, at the San Diego Convention Center. 

The 2016 ASH Annual Meeting will feature nearly 5,000 scientific abstract presentations in malignant and non-malignant blood diseases – from cutting-edge advances in genome editing and discoveries about biological processes of the blood to practice-changing breakthroughs in immunotherapies and innovative treatment combinations. The top six abstracts will be presented during the Plenary Scientific Session on Sunday, and the Late-Breaking Abstracts Session on Tuesday will feature six studies with novel data of high-impact. In addition to these signature sessions, experts will analyze abstracts in the transformative fields of genome editing and novel approaches to immunotherapy in this year’s two Featured Topic Discussions.

“The ASH Annual Meeting is internationally notable for its unparalleled educational and scientific programming and its assortment of sessions on malignant and non-malignant hematology,” said ASH President Charles S. Abrams, MD, of the University of Pennsylvania. “What is so special about this meeting is that it serves as the largest meeting place for hematologists in the world – it is our largest stage for the year’s important discoveries, and it is the place where collaborations are formed. I am honored to welcome hematologists and other health professionals from all over the world to join us in San Diego.”

Beyond the research presented in the abstract presentations, ASH is pleased to host Greg Simon, executive director of the White House Cancer Moonshot Taskforce, as the guest speaker at its annual Grassroots Network Lunch. The Grassroots Network Lunch is a forum for ASH members to learn how they can get involved in the Society’s advocacy efforts throughout the year. In addition, the ASH Annual Meeting offers programming specifically for trainees, including a half-day career-development workshop the day before the meeting. 

ASH’s new open-access journal, Blood Advances, will launch at the meeting with a commemorative print copy, remarks at the start of the Plenary Scientific Session by Editor-in-Chief Robert Negrin, MD, of Stanford University, and other surprises for attendees.

Other noteworthy annual meeting offerings include the Presidential Symposium, Education and Scientific Programs, and a wide array of lectures, seminars, special symposia, and recognition of the Society’s prestigious honorific and mentor award recipients:

For the complete annual meeting program and abstracts, visit www.hematology.org/annual-meeting or download ASH’s annual meeting mobile app. Up-to-the-minute meeting information can also be found by following ASH on Twitter (@ash_hematology) and the meeting hashtag #ASH16


The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.  

CONTACT:
Sara Khalaf, American Society of Hematology
skhalaf@hematology.org; 202-552-4925

58th ASH Annual Meeting to Celebrate Major Advances in Hematology Research

58th ASH Annual Meeting to Celebrate Major Advances in Hematology Research

News

2 years
4 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Acute Lymphoblastic Leukemia
14 Views
kidneycancer 9 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
1 Views
UVA Cancer Center 10 hours
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
2 Views
Cancer-News 13 hours
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
10 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 1 day
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 1 day
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 1 day